Skip to main content

Table 3 Treatment response

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

 

Total (n = 94)

CC (n = 46)

CP (n = 48)

Best response

   

Complete response

2 (2 %)

0 (0 %)

2 (4 %)

Partial response

52 (55 %)

26 (57 %)

26 (54 %)

Stable disease

22 (23 %)

10 (22 %)

12 (25 %)

Progressive disease

7 (7 %)

3 (7 %)

4 (8 %)

Not evaluable

11 (12 %)

7 (15 %)

4 (8 %)

Overall response rate

54 (57 %)

26 (57 %)

28 (58 %)

Disease control rate

76 (81 %)

36 (78 %)

40 (83 %)